Business
NuLife Announces Planned Merger with Ensysce Biosciences
NuLife Announces Planned Merger with Ensysce Biosciences.
About this update from Gulf West Security Network Inc.
[{"type":"text","content":"\nNuLife Announces Planned Merger with Ensysce Biosciences\n\nNuLife Announces Planned Merger with Ensysce Biosciences\n\n\nCompany will develop proprietary technologies to address opioid abuse epidemic \n\nNEWPORT BEACH, CA--(Marketwired - October 31, 2017) - NuLife Sciences (OTCQB: NULF) today announced the signing of a letter of intent to undertake a formal merger with Ensysce Biosciences of San Diego, California, a clinical stage company with delivery platforms for both small and large molecule therapies.Ensysce's BIO-MD™ is a prodrug delivery platform that provides abuse deterrence to a long list of prescription drugs, including opioid products. The prodrugs are activated in a 2-step, enzyme mediated reaction only after oral administration. This process removes the patient's ability to abuse the drug by inhalation or through kitchen chemistry and intravenous injection. Ensysce has recently completed a Phase 1 trial with its lead oxycodone prodrug, PF614. The trial results in 48 subjects, randomized to receive PF614 or Oxycontin, showed over 90% efficient release of oxycodone and an improved safety profile over OxyContin™. The merged company will focus on proprietary delivery technologies to combat drug abuse and overdose, particularly with opioids. As prescriptions for opioids have risen sharply over the last two decades, rates of addiction and overdose deaths have dramatically increased. Drug overdose deaths are now the leading cause of accidental death in the U.S., exceeding deaths caused by motor vehicle accidents, guns and HIV infection. The number of overdose deaths involving specifically opioids, including prescription opioids and heroin, has quadrupled since 1999. The epidemic has led to President Trump recently declaring the drug and opioid crisis a national emergency. Another promising delivery platform in development for large biomolecules, single walled carbon nanotubes (SWCNT), offers a novel approach for the intravenous delivery of immunology and gene therapy products. Ensysce is exploring the possibility for SWCNT to become an off-the-shelf delivery platform for CAR-T and CRISPR. CAR-T (Chimeric Antigen Receptor T Cells) is a rapidly emerging immunotherapy approach to treating a patient's cancer by collecting and using the patient's own immune cells. CRISPR (Clustered Regularly Interspaced Short Pa...